Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1

Zijun Zhang, Min Jin Ha, Changxing Qi, Xiaotian Zhang, Yang Xiao, Chengjuan Chen, Yu Zou, Xia Chen, Lianghu Gu, Jianzheng Huang, Kun Huang, Ming Xiang, Tiantai Zhang, Qingyi Tong, Yonghui ZhangMedComm 2025 · DOI

TL;DR

This study identifies Butyrolactone I (BLI), a natural product, as a potent inhibitor of JAK1, a key signaling molecule. BLI effectively prevents the progression from acute kidney injury (AKI) to chronic kidney disease (CKD) in mouse models by reducing inflammation, fibrosis, and ferroptosis, offering a promising new therapeutic avenue for kidney disease.

What Problem Does This Paper Address?

Chronic kidney disease (CKD) is a global health crisis affecting over 850 million people, with acute kidney injury (AKI) being a major contributor to its development and progression. The transition from AKI to CKD is driven by complex mechanisms including inflammation, oxidative stress, and fibrosis. Current treatments for CKD are limited, and there's an urgent need for effective strategies to block this AKI-to-CKD transition. This paper addresses this gap by investigating the potential of a natural compound, Butyrolactone I (BLI), to prevent this detrimental progression.

Methods

The researchers employed a multi-pronged approach:

  • In vivo studies: They used established mouse models of AKI-CKD transition, induced by folic acid (FA) and unilateral ureteral obstruction (UUO). These models allowed them to assess BLI's effects on kidney function, inflammation, fibrosis, and ferroptosis.
  • Biochemical assays: Blood urea nitrogen (BUN), creatinine (Cr), and microalbuminuria (MAU) levels were measured to evaluate kidney function. Serum and kidney tissue levels of inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α) were assessed.
  • Histopathology: Hematoxylin and eosin (H&E) staining, Masson's trichrome staining, and immunohistochemistry were used to examine kidney tissue structure, fibrosis, and the infiltration of inflammatory cells (macrophages).
  • Molecular biology techniques: RNA sequencing (RNA-seq) was performed to identify pathways affected by BLI. RT-qPCR was used to quantify the expression of specific genes related to kidney injury and ferroptosis. Immunoblotting was employed to measure protein levels.
  • Target identification and validation: Bioinformatics analysis, molecular dynamics simulations, CETSA (Cellular Thermal Shift Assay), DARTS (Drug Affinity Responsive Target Stability), and kinase activity assays were used to identify JAK1 as BLI's direct target and confirm its inhibitory activity.
  • JAK1 knockdown studies: Gene-edited mice with reduced JAK1 expression were used to confirm JAK1's essential role in BLI's nephroprotective effects.
  • Cell-based assays: In vitro studies using HK2 and NRK-52E kidney cells were conducted to further investigate BLI's effects on ferroptosis and its interaction with JAK1.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from mouse models and cell cultures.

Key Insights and Ideas

  • BLI as a potent JAK1 inhibitor: The most significant finding is the identification of BLI as a direct and potent inhibitor of JAK1, a crucial kinase in inflammatory and cellular stress pathways. This is a novel discovery for BLI.
  • BLI's superiority over telmisartan: In the FA-induced AKI-CKD model, BLI demonstrated superior reduction in blood urea nitrogen and stronger anti-inflammatory effects compared to telmisartan, a standard treatment for kidney disease.
  • Multi-faceted nephroprotection: BLI's protective effects are not limited to a single mechanism. It simultaneously tackles inflammation, fibrosis, and ferroptosis, which are all key drivers of AKI-to-CKD progression.
  • Ferroptosis as a critical target: The study strongly implicates ferroptosis (a form of programmed cell death driven by iron accumulation) as a key mechanism through which BLI exerts its protective effects, particularly by modulating the JAK-STAT pathway.
  • JAK1 dependency of BLI's action: The use of JAK1-knockdown mice definitively proves that BLI's nephroprotective effects are mediated through its interaction with JAK1.

Key Results

  • BLI significantly improved kidney function markers (reduced BUN, Cr, MAU) in both FA- and UUO-induced AKI-CKD mouse models.
  • BLI markedly reduced the expression of pro-inflammatory cytokines and the infiltration of macrophages in kidney tissues.
  • BLI effectively inhibited kidney fibrosis by reducing the deposition of extracellular matrix components like collagen and fibronectin.
  • BLI significantly suppressed ferroptosis by normalizing MDA and GSH levels, reducing 4-HNE, and modulating the expression of key ferroptosis-related proteins (GPX4, SLC7A11, FSP1, FTH1, FTL, TfR1).
  • BLI directly binds to JAK1 with a high affinity and inhibits its kinase activity with an IC50 of 0.376 µM.
  • BLI demonstrated nephroprotective effects and safety comparable to ivarmacitinib, a known JAK1 inhibitor.
  • Histological analysis showed that BLI treatment preserved kidney tissue structure and reduced damage in the treated mice.

Limitations and Future Work

  • Complexity of BLI's mechanism: The authors acknowledge that the mechanism by which BLI targets JAK1 for nephroprotection might be more complex than currently understood and requires further in-depth investigation with advanced techniques.
  • Progressive CKD models: The study focused on the AKI-CKD transition. Future research should explore BLI's effects on animal models of progressive CKD.
  • Metabolism and drug candidate potential: The metabolism of BLI and its evaluation as a drug candidate are important areas for future research.
  • Other CKD types: The potential of BLI in other CKD subtypes, such as diabetic kidney disease (DKD), warrants further investigation.

Summary updated

Abstract

Chronic kidney disease (CKD) is a disease that affects more than 850 million people. Acute kidney injury (AKI) is a common cause of CKD, and blocking the AKI-CKD transition shows promising therapeutic potential. Herein, we found that butyrolactone I (BLI), a natural product, exerts significant nephroprotective effects, including maintenance of kidney function, inhibition of inflammatory response, and prevention of fibrosis, in both folic acid- and ureteral obstruction-induced AKI-CKD transition mouse models. Notably, BLI showed greater blood urea nitrogen reduction and anti-inflammatory effects than telmisartan. Bioinformatics analysis and target confirmation assays suggested that BLI directly binds to JAK1, and kinase inhibition assay confirmed it is a potent JAK1inhibitor with an IC<sub>50</sub> of 0.376 µM. Experiments in JAK1-knockdown mice also proved that BLI targets JAK1 to work. Furthermore, BLI demonstrated nephroprotective effects and safety comparable to ivarmacitinib, the well-known JAK1 inhibitor. Mechanistically, BLI targets JAK1 and inhibits its phosphorylation and JAK-STAT activation, subsequently regulating the downstream signaling pathways to inhibit reactive oxygen species production, inflammation, and ferroptosis, thereby preventing the occurrence of kidney fibrosis and blocking the AKI-CKD transition process. This study demonstrates for the first time that BLI is a JAK1 inhibitor and a promising candidate for delaying CKD progression, which warrants further investigation.
BibTeX
@inproceedings{zhang2025butyrolactone,
  author = {Zijun Zhang and Min Jin Ha and Changxing Qi and Xiaotian Zhang and Yang Xiao and Chengjuan Chen and Yu Zou and Xia Chen and Lianghu Gu and Jianzheng Huang and Kun Huang and Ming Xiang and Tiantai Zhang and Qingyi Tong and Yonghui Zhang},
  title = {{Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1}},
  booktitle = {MedComm},
  year = {2025},
  doi = {10.1002/mco2.70064},
}
Figure